Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ALLO-647

Monoclonal antibody · Kills target cells, directed at CD52 · developed by Allogene Therapeutics

Phase 1/2 Most advanced trial

ALLO Developer

1 Registered trials

What is ALLO-647?

ALLO-647 is a monoclonal antibody that binds CD52, a glycoprotein on B and T lymphocytes. Upon binding, it triggers immune-mediated lysis of CD52-positive cells. It is studied in relapsed or refractory large B cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Targets: CD52
Mechanism: Kills target cells, directed at CD52
Pathways: immune cell lysis, immunodepletion
Therapy area: Oncology
Developer: Allogene Therapeutics (ALLO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04416984	Phase 1/2	Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic…	Active not recruiting	ALLO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ALLO page.

Follow ALLO, the company behind ALLO-647

See ALLO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALLO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z